Study Evaluating Venlafaxine ER in Adults With Panic Disorder
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Panic Disorder
Intervention: Venlafaxine ER (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
The primary objective of this study is to determine the efficacy, safety, and tolerability
of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks
in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase
III study.
Clinical Details
Official title: A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder
Study design: Primary Purpose: Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A male or female outpatient
- Be at least 18 years of age and legal age of consent
- Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months
before study day 1
Exclusion Criteria:
- Treatment with venlafaxine (IR or ER) within 6 months of study day 1
- Known hypersensitivity to venlafaxine (IR or ER) or related compounds
- History or presence of any clinically important hepatic, renal, or other medical
disease that might compromise the study or be detrimental to the patient (eg,
clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
cell epithelioma], uncontrolled hypertension)
Locations and Contacts
Additional Information
Starting date: April 2001
Last updated: August 13, 2009
|